Clinical and Pathologic Complete Response to Gefitinib in a Patient with SqCLC Harboring EGFR p.E746_S752delinsV Mutation.
Weitao ZhuangChao ZhangYong TangDan TianZihua LanCheng ZengGuibin QiaoPublished in: OncoTargets and therapy (2021)
Development of targeted therapies for squamous cell lung cancer (SqCLC) is currently limited by the prevalence of activating mutations and their predicting power of treatment efficacy. In the present study, we describe a case of treatment-naïve stage IIIB SqCLC that harbored a rare epidermal growth factor receptor (EGFR) p.E746_S752delinsV mutation with clinical complete response to neoadjuvant gefitinib. Pathological complete response was confirmed after surgical resection. No disease recurrence was documented after 20-month follow-up. This report suggested that first-generation EGFR tyrosine kinase inhibitor (TKI) could be an option in neoadjuvant context for advanced SqCLC patients harboring EGFR p.E746_S752delinsV mutation and highlighted the clinical benefits of EGFR testing in SqCLC patients who are females and never/former light smokers.
Keyphrases
- epidermal growth factor receptor
- tyrosine kinase
- small cell lung cancer
- advanced non small cell lung cancer
- end stage renal disease
- ejection fraction
- lymph node
- rectal cancer
- newly diagnosed
- squamous cell
- locally advanced
- prognostic factors
- risk factors
- patient reported outcomes
- radiation therapy
- signaling pathway
- neoadjuvant chemotherapy